Holista Colltech Limited
(ASX:HCT / ABN 24 094 515 992)
283 Rokeby Road Subiaco WA 6008
P: +61 412 474 180
W: www.holistaco.com

Appendix 4C and Activities Report: September 2026 Quarterly Update; Continued Focus on Cash Management

ASX Announcement

30 October 2026

Holista Colltech Limited (ASX: HCT, "Holista" or "the Company") provides the following operational and financial update for the quarter ended 30 September 2026, together with the accompanying Appendix 4C. The report also includes relevant developments following quarter-end.

Key Highlights

- Group revenue was approximately $1.58 million, compared with $1.50 million in the previous quarter, an increase of 5.2%.
- Customer receipts increased 12.4% to approximately $1.66 million, mainly due to customer deposits and debt recoveries.
- The Company paid the second and final tranche of the ProImmune legal settlement during the quarter, amounting to approximately $1.159 million.
- Excluding the one-off ProImmune settlement payment, operating cash flow was positive at approximately $318,000, compared with $149,000 in the previous quarter.
- Due to additional regulatory and building approval requirements, commencement of operations at the Collie collagen manufacturing facility is now targeted for May–July 2027.

Financial Overview

During the quarter ended 30 September 2026, Group revenue was approximately $1.58 million, compared with $1.50 million in Q2 FY2026. The Supplements

division remained the main revenue contributor, while movements in other divisions largely reflected customer order and delivery timing.

Customer receipts increased to approximately $1.66 million from $1.48 million in the preceding quarter, mainly due to deposits received and recovery of overdue debts.

Net cash used in operating activities was approximately $841,000, compared with $1.29 million in Q2 FY2026. Both quarters included one-off ProImmune legal settlement payments: $1.436 million for the first tranche in Q2 FY2026 and $1.159 million for the second and final tranche in Q3 FY2026.

Excluding these one-off payments, operating cash flow would have been positive at approximately $318,000 in Q3 FY2026, compared with $149,000 in Q2 FY2026. These adjusted figures are provided for comparison and do not represent statutory operating cash flow.

Investing activities

Net cash used in investing activities was approximately $2,000 in Q3 FY2026, relating to the replacement of ageing computer equipment.

Financing activities


Net cash generated from financing activities was approximately $321,000 in Q3 FY2026, mainly from $371,000 in proceeds of the convertible loan used to fund part of the ProImmune settlement. Other borrowing proceeds and repayments largely offset each other.

Cash and cash equivalents at 30 September 2026 were $23,000. Including approximately $1.47 million in unused financing facilities, total available funding at quarter-end was approximately $1.49 million.

Based on the quarter’s reported net operating cash outflow, the Company reported approximately 1.77 quarters of available funding. Further details of the funding position and plans are provided in the accompanying Appendix 4C.

The Company continues to monitor its cash position and assess available financing and capital management options to support ongoing operations.

In accordance with ASX Listing Rule 4.7C, no payments were made to related parties or their associates during the quarter.




**FY2025 figures have been adjusted to audited figures.*
FY2026 figures are subject to audit.

Divisional Performance

Group revenue was approximately $1.58 million, up 5.2% compared with the preceding quarter. The Supplements division remained the largest contributor. Variations in the other divisions were mainly attributable to the timing of orders and deliveries.

- **Supplements:** Sales were approximately $1.39 million, compared with $1.44 million in the preceding quarter.
- **Food Ingredients:** Sales were approximately $138,000, compared with $19,000 in the preceding quarter, reflecting the timing of orders and deliveries.
- **Ovine Collagen:** Sales were approximately $26,000, compared with $29,000 in the preceding quarter.
- **Infection Control / Agriculture:** Sales were approximately $27,000, compared with $10,000 in the preceding quarter, reflecting continued customer orders following successful trial runs.



**FY2025 figures have been adjusted to audited figures.*
FY2026 figures are subject to audit.

Corporate Update

1. ProImmune Litigation

The Company fully settled the ProImmune legal settlement with a second and final payment of US$800,000 on 10 July 2026, equivalent to approximately $1.159 million in the Q3 cash flow. The first tranche payment of US$1.0 million, equivalent to approximately $1.436 million, was made during Q2 FY2026.

The payments were non-recurring and substantially affected reported operating cash flows in both quarters.

2. Convertible Loan

On 9 July 2026, the Company announced an unsecured convertible loan of $370,724 from Powerwind Plantation Sdn Bhd to fund part of the ProImmune legal settlement. The funding was received during Q3 FY2026. The loan bears interest at 8% per annum and is convertible at the lender's election into 5,296,055 ordinary shares at $0.07 per share, subject to shareholder approval.

3. Ovicoll and Collie Plant Update

Joint Venture Structure and Management

The Collie collagen manufacturing facility is being developed by Ovicoll Pty Ltd ("Ovicoll"), a 50:50 joint venture between Holista Colltech Limited ("Holista") and Swang Chai Chuan Limited ("SCC"), a company listed on the Hong Kong Stock Exchange (Stock Code: 2321). Ovicoll has completed the acquisition of the land in Collie, Western Australia, for the manufacturing facility.

SCC contributed RM5.0 million (approximately A$1.76 million) to the joint venture, and Ovicoll received the funds on 18 May 2026.

The Holista representatives on the Ovicoll Board are Leong Man Loong and Robert Gemelli, while SCC is represented by Soon See Beng and Soon Chiew Ang, all serving as Directors. Jay Stephenson serves as Company Secretary, while Stantons acts as the external auditor.

HCT, led by Robert Gemelli, oversees the overall product management and collaborates with teams in Malaysia and Hong Kong, as well as the critical on-the-ground approval process in Collie.

HCT transferred the employment of its Collie-based Plant Manager, Nilesh Shah, to Ovicoll effective 1 July 2026.

Collie Plant Development

The Company continued to progress the development of the collagen manufacturing facility in Collie. The plant design is substantially finalised, while the Development Application (DA) remains under review by the Shire of Collie.

Building Approvals Pathway

The original approvals pathway was based on the initial construction assessment that the project could be treated as a standard shed development, requiring only a DA and building permit.

Following further assessment, additional regulatory and building approval requirements have been identified because of the planned advanced nano collagen manufacturing activities. Specialist consultants will manage the approval process, while the existing construction contractor will remain responsible for the building works.

The facility has a planned total floor area of 868.9 m², including a 215.4 m² Nano Collagen Site, a laboratory, clean room and cool rooms. The facility is proposed to be classified as a Class 8 processing building under the National Construction Code (NCC).

As the facility will process sheepskins, use chemicals and generate regulated waste, the project is subject to further environmental and building assessments, including:

- Assessment of works approval and operating license requirements by the Department of Water and Environmental Regulation (DWER), subject to confirmation of the applicable regulatory requirements. The estimated assessment period is approximately three months.
- Possible public advertising of the Development Application.
- An NCC design review, including referral to the Department of Fire and Emergency Services (DFES), where required.

- Building certification and the necessary building permit.

Requests for additional information during the assessment process may extend the approval timeframe. Complete submissions will therefore be important in managing the approval schedule.

Revised Project Timeline

After the full DA was lodged in early September 2026, the Shire raised a query requiring further clarification.

As a result, the original target to commence operations in December 2026 is no longer achievable due to additional regulatory and building approval requirements.

Based on the current project assessment, the necessary approvals are expected to be completed no earlier than January–February 2027. Shed fabrication, erection, equipment installation and fit-out will follow.

Initial production is currently targeted for May–July 2027. These dates remain indicative and are subject to regulatory assessment timeframes, construction progress and commissioning requirements. No activities requiring an operating license will commence until the relevant approvals have been obtained.

Sufficient Inventory to Meet Ongoing Customer Orders

The Company continues to meet ongoing customer orders using existing inventory held in Kuala Lumpur, which is expected to be sufficient to meet demand for the first half of 2027.

New Customers and Product Regulatory Pathway

The Company continues to work with Regenerex Pharma to finalise and develop products for the North American wound care market.

Working with Regenerex, the Company is also progressing the US Food and Drug Administration (FDA) 510(k) premarket clearance process, CE marking requirements for the European market, and registration of the relevant device and manufacturer details in the European Database on Medical Devices (EUDAMED). These activities are supported by consultants based in Tennessee and Amsterdam, respectively.

Intellectual Property Development – Ovine Collagen Portfolio

The patenting process continues with filing in the United States and Australia. During the quarter, the Company commenced work on three areas of development within its Australian ovine collagen intellectual property (IP) portfolio:

Track 1 – US Patent Application

The Company is preparing a Request for Continued Examination of US Patent Application No. 18/208,249 ahead of the 31 October 2026 deadline. Experimental results demonstrate a 74-fold reduction in endotoxin levels.

Track 2 – HOCl-Resistant Collagen Scaffold

The Company is progressing a US provisional patent application for an HOCl-resistant ovine collagen scaffold intended for chronic wound care applications, supported by ongoing laboratory studies.

Track 3 – Nano-Copper Pelt Pretreatment

Preliminary trials using nano-copper pretreatment showed a reduction of more than 5.3 $\log_{10}$ in aerobic microbial count compared with untreated pelts. The Company has commissioned further confirmatory testing to support a Continuation-in-Part patent application targeted for November 2026.

The Company's Australian ovine collagen, described as having negligible transmissible spongiform encephalopathy (TSE) risk and being compatible with Halal and Kosher requirements, forms the basis of these development activities.

Patent applications remain subject to examination and approval, and the grant of patents is not guaranteed. Certain experimental results are preliminary and remain subject to further validation.

-ENDS-

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
HOLISTA COLLTECH LIMITED (ASX: HCT)	
ABN	Quarter ended ("current quarter")
24 094 515 992	**30 September 2026**

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	1,664	4,457
1.2	Payments for:		
	(a) research and development	(22)	(32)
	(b) product manufacturing and operating costs	(681)	(2,319)
	(c) advertising and marketing	(122)	(156)
	(d) leased assets	-	-
	(e) staff costs	(348)	(1,120)
	(f) administration and corporate costs	(135)	(414)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	11
1.5	Interest and other costs of finance paid	(22)	(68)
1.6	Income taxes paid	(16)	(47)
1.7	Government grants and tax incentives	-	-
1.8	Other (ProImmune legal settlement)	(1,159)	(2,595)
1.9	**Net cash from / (used in) operating activities**	**(841)**	**(2,283)**
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(2)	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from the disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) Investments	-	118
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(2)**	**116**
3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	371	371
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,330	4,160
3.6	Repayment of borrowings	(1,380)	(4,434)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**321**	**97**
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	564	2,161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(841)	(2,283)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	116
4.4	Net cash from / (used in) financing activities (item 3.10 above)	321	97
4.5	Effect of movement in exchange rates on cash held	(19)	(68)
4.6	**Cash and cash equivalents at end of period**	**23**	**23**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	23	*564
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (Restricted Cash)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**23**	**564**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

* The closing cash balance as at 30 June 2026 was incorrectly reported as A$526,000 in the Q2 FY2026 Appendix 4C due to an omission of the effect of exchange rate movements on cash held. The correct balance was A$564,000, which has been reflected as the opening cash balance in the current quarter.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	399	399
7.2	Credit standby arrangements	2,283	817
7.3	Other (please specify)		
7.4	**Total financing facilities**	**2,682**	**1,216**

7.5	**Unused financing facilities available at quarter end**	**1,466**

7.6 Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Summary of Banking Facilities:

Bank Loan Facility 1:

Parties: CIMB Islamic Bank Berhad Malaysia (**Banker**), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Colltech Limited) (**Borrower**).

i) Loan Facility 1

Term Loan

Principal Amount: MYR 1.4M / approximately A$492K

Remaining Payable as at 30 September 2026: MYR 1.09M / approximately A$382K

Term: Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of $3,057 (2025: $3,204) and ending in 200 months on 4 October 2040.

Interest Rate: 3.50% per annum (2025: 3.74%).

ii) Credit Standby Arrangement 1

Trade Financing and Banker Acceptances bears interest of 5.03% per annum (2025: 4.83%).

Total Amount at Quarter End: MYR 2M / Approximately A$702K

Total Utilised at Quarter End: MYR 1,154K / Approximately A$405K

Bank Loan Facility 1 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Facility agreement;
- First party assignment over the office lots of the Company;
- Deed of assignment of rental proceeds;
- Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and
- Guarantee by a director of the Company.

Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi Currency Trade Financing-i**", to facilitate local and export sales of the Borrower; and
- "**Bank Guarantee**", for issuance of financial, performance and security bonds to government and private entities, in relation to business.

Bank Loan Facility 2:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Loan Facility 2

Term Loan

Principal Amount: MYR 200K / approximately A$70K.

Amount Remaining as at 30 September 2026: MYR 48K / approximately A$17K

Term: Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of A$1,379 (2025: A$1,423) and ending in 44 months on 4 November 2027.

Interest Rate: 3.68% per annum (2025: 3.68%).

ii) Credit Standby Arrangement 2

Trade Financing and Banker Acceptance bears interest of 5.03% per annum (2025: 5.19%).

Total Amount at Quarter End: MYR 1.5M / Approximately A$527K

Total Utilised at Quarter End: MYR 1,173K / Approximately A$412K

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi Currency Trade Financing-i**", to facilitate local and export sales of the Borrower;
- "**Documentary Credit-i**", to facilitate local and import purchases of the Borrower;
- "**Accepted Bills-i 2**", to facilitate local and import purchases of the Borrower; and
- "**Multi Currency Trade Financing-i 2**", to facilitate local and import purchases of the Borrower.

Bank Loan Facility 3:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Credit Standby Arrangement 3

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

Total Amount at Quarter End: MYR 3.0M / Approximately A$1,053K

Total Utilised at Quarter End: MYR nil / Approximately A$ nil

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi-Currency Trade Financing-i**", to facilitate local and export sales of the Borrower;
- "**Documentary Credit-i**", to facilitate local and import purchases of the Borrower;
- "**Accepted Bills-i 2**", to facilitate local and import purchases of the Borrower; and
- "**Multi-Currency Trade Financing-i 2**", to facilitate local and import purchases of the Borrower.

8.	Estimated cash available for future operating activities	$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(841)
8.2	Cash and cash equivalents at quarter end (item 4.6)	23
8.3	Unused finance facilities available at quarter end (item 7.5)	1,466
8.4	Total available funding (item 8.2 + item 8.3)	**1,489**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**1.77**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No. The Company does not expect the current level of net operating cash outflows to continue. The reported quarter included the second and final payment of US$0.8 million under the ProImmune litigation settlement. Following completion of the settlement, the Company expects operating cash outflows to reduce, subject to normal operating and working capital requirements.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: The Company currently has access to unused funding facilities totalling approximately $1.466 million. It expects to meet its operating cash requirements through a combination of these facilities, existing working capital and, where appropriate, additional capital raising if required.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The Company expects to continue its operations and meet its business objectives based on the non-recurring nature of the ProImmune settlement payment referred to in section 8.6.1, together with the availability of unused funding facilities, existing working capital and ongoing management of operating cash flows.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.